Posted by Michael Wonder on 19 Jul 2021
Decision to widen access to rituximab for people with B-cell acute lymphoblastic leukaemia/lymphoma
9 July 2021 - PHARMAC is widening access to rituximab (Riximyo) to include treatment of people with newly diagnosed B-cell acute lymphoblastic leukaemia/lymphoma (B-cell ALL).
From 1 August 2021, people with B-cell ALL who meet the funding criteria will be eligible for funded access to rituximab.
